GU Cancers 2026 | Enhancing toxicity management with EV-pembrolizumab in bladder cancer
Daniel Petrylak, MD, Yale University, New Haven, CT, discusses the importance of toxicity management in the treatment of bladder cancer with enfortumab vedotin (EV) and pembrolizumab. Effective patient and physician education programs are needed to manage side effects, where community physicians may have less experience with bladder cancer and EV, leading to potential reluctance to prescribe the drug due to toxicity concerns. This interview took place at the 2026 ASCO GU Cancers Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I think that the optimization comes from toxicity management. One of the things that happens out in practices is that the frequency of patients who are seen with bladder cancer is probably smaller than in an academic center. So I’ve had more than 12 years of experience in giving EV, so I’m very used to any side effects that may come forth. If somebody has one or two bad experiences, then they may be less inclined to give that particular drug...
I think that the optimization comes from toxicity management. One of the things that happens out in practices is that the frequency of patients who are seen with bladder cancer is probably smaller than in an academic center. So I’ve had more than 12 years of experience in giving EV, so I’m very used to any side effects that may come forth. If somebody has one or two bad experiences, then they may be less inclined to give that particular drug. So what really is needed are good patient and physician education programs about how to manage toxicities with this drug.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
